European Heart Journal Advance Access originally published online on June 14, 2007
European Heart Journal 2007 28(13):1598-1660; doi:10.1093/eurheartj/ehm161
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes,
The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members,
(France)
(Germany)
(Italy)
(The Netherlands)
(Poland)
(Spain)
(UK)
(Israel)
(USA)
(Sweden)
(Belgium)
ESC Committee for Practice Guidelines (CPG),
France
(UK)
(Italy)
(France)
(Norway)
(Greece)
(Denmark)
(Czech Republic)
(France)
(Germany)
(Poland)
(The Netherlands)
(Spain)
(Germany)
(France)
Document Reviewers,
(CPG Review Coordinator) ( Denmark)
(Italy)
(Austria)
(France)
(Spain)
(Italy)
(Belgium)
(Germany)
(Spain)
(Germany)
(Israel)
(Austria)
(Israel)
(Spain)
(Portugal)
(Norway)
(Germany)
(France)
(Denmark)
(Italy)
(Canada)
(The Netherlands)
(Switzerland)
* Corresponding authors. Chair: Jean-Pierre Bassand, Department of Cardiology, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besançon, France. Tel: +33 381 668 539; fax: +33 381 668 582. E-mail address: jean-pierre.bassand@ufc-chu.univ-fcomte.fr Co-chair: Christian W. Hamm Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany. Tel: +49 6032 996 2202; fax: +49 6032 996 2298. E-mail address: c.hamm@kerckhoff-klinik.de
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.
Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where
| Preamble |
|---|
| 1. Introduction and definitions |
|---|
| 2. Epidemiology and natural history |
|---|
| 3. Pathophysiology |
|---|
3.1 The vulnerable plaque
3.2 Coronary thrombosis
3.3 The vulnerable patient
3.4 Endothelial vasodilatory dysfunction
3.5 Accelerated atherosclerosis
3.6 Secondary mechanisms
3.7 Myocardial injury
| 4. Diagnosis and risk assessment |
|---|
4.1 Clinical presentation and history
4.2 Diagnostic tools
4.2.1 Physical examination
4.2.2 Electrocardiogram
Continuous ST-segment monitoring
Exercise or other stress testing
4.2.3 Biochemical markers
Markers of myocardial injury
Markers of inflammatory activity
Markers of neurohumoral activation
Markers of renal function
Novel biomarkers
Multimarker approach
Point-of-care (bedside) biomarker testing
4.2.4 Echocardiography and non-invasive myocardial imaging
4.2.5 Imaging of the coronary anatomy
4.3 Differential diagnoses
4.4 Risk scores
| 5. Treatment |
|---|
5.1 Anti-ischaemic agents
5.1.1 Beta-blockers
5.1.2 Nitrates
5.1.3 Calcium channel blockers
5.1.4 New drugs
5.2 Anticoagulants
5.2.1 Unfractionated heparin
Pharmacology
Treatment effects
5.2.2 Low molecular weight heparin
Pharmacology
Treatment effects
5.2.3 Factor-Xa inhibitors
Pharmacology
Treatment effects
5.2.4 Direct thrombin inhibitors
Pharmacology
Treatment effects
5.2.5 Vitamin K antagonists
5.2.6 Anticoagulants during percutaneous coronary intervention procedures in non-ST-segment elevation acute coronary syndromes
5.3 Antiplatelet agents
5.3.1 Acetylsalicylic acid (aspirin)
5.3.2 Thienopyridines
Risk of bleeding
Dose and timing of clopidogrel
5.3.3 Glycoprotein IIb/IIIa receptor inhibitors
Glycoprotein IIb/IIIa inhibitors in a conservative strategy
Glycoprotein IIb/IIIa inhibitors in an invasive strategy
Use of glycoprotein IIb/IIIa inhibitors prior to revascularization
Adjunctive therapy
5.3.4 Resistance to antiplatelet agents/drug interactions
Aspirin resistance/drug interactions
Clopidogrel resistance/drug interactions
5.3.5 Withdrawal of antiplatelet agents
5.4 Coronary revascularization
5.4.1 Coronary angiography
5.4.2 Invasive vs. conservative strategy
Choice of strategy
Timing of invasiveness
5.4.3 Percutaneous coronary intervention
5.4.4 Coronary artery bypass graft
5.4.5 Respective indications for percutaneous coronary intervention or coronary artery bypass graft
5.5 Long-term management
5.5.1 Lifestyle
5.5.2 Weight reduction
5.5.3 Blood pressure control
5.5.4 Management of diabetes
5.5.5 Interventions on lipid profile
Statins
Other lipid-lowering agents
5.5.6 Antiplatelet agents and anticoagulants
5.5.7 Beta-blockers
5.5.8 Angiotensin-converting enzyme inhibitors
5.5.9 Angiotensin-2 receptor blockers
5.5.10 Aldosterone receptor antagonists
5.6 Rehabilitation and return to physical activity
| 6. Complications and their management |
|---|
6.1 Bleeding complications
6.1.1 Predictors of bleeding risk
6.1.2 Impact of bleeding on prognosis
6.1.3 Management of bleeding complications
6.1.4 Impact of blood transfusion
6.2 Thrombocytopenia
6.2.1 Heparin-induced thrombocytopenia
6.2.2 Glycoprotein IIb/inhibitor-induced thrombocytopenia
| 7. Special populations and conditions |
|---|
7.1 The elderly
7.1.1 Early diagnostic evaluation in the elderly
7.1.2 Therapeutic considerations
7.2 Gender
7.2.1 Glycoprotein IIb/IIIa inhibitors in women
7.2.2 Revascularization and early invasive strategy among women
7.3 Diabetes mellitus
7.4 Chronic kidney disease
7.4.1 Chronic kidney disease as a marker of risk of coronary artery disease
7.4.2 Contrast-induced nephropathy
7.4.3 Management of chronic kidney disease in patients with coronary artery disease
7.4.4 Biomarkers in chronic kidney disease
7.5 Anaemia
7.6 Normal coronary arteries
| 8. Management strategies |
|---|
8.1 First step: initial evaluation
8.2 Second step: diagnosis validation and risk assessment
8.2.1 Diagnosis validation
8.2.2 Risk assessment
8.3 Third step: invasive strategy
8.3.1 Conservative strategy
8.3.2 Urgent invasive strategy
8.3.3 Early invasive strategy
8.4 Fourth step: revascularization modalities
8.5 Fifth step: discharge and post-discharge management
| 9. Performance measures |
|---|
| 10. Abbreviations |
|---|
| 11. Trial acronyms |
|---|
| Acknowledgements |
|---|
| Footnotes |
|---|
| References |
|---|
This article has been cited by other articles:
![]() |
C. P Gale, A. D Simms, B. A Cattle, D. Greenwood, and R. M West Point of care testing in acute coronary syndromes: when and how? Heart, July 15, 2009; 95(14): 1128 - 1129. [Full Text] [PDF] |
||||
![]() |
F. Schiele, N. Meneveau, M. F. Seronde, R. Chopard, V. Descotes-Genon, J. Dutheil, J.-P. Bassand, and on behalf on the 'Reseau de Cardiologie de Franche C-reactive protein improves risk prediction in patients with acute coronary syndromes Eur. Heart J., July 4, 2009; (2009) ehp273v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Di Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna, and A. Montinaro Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial J. Am. Coll. Cardiol., July 1, 2009; (2009) j.jacc.2009.05.028v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. van Werkhoven, J. D. Schuijf, O. Gaemperli, J. W. Jukema, L. J. Kroft, E. Boersma, A. Pazhenkottil, I. Valenta, G. Pundziute, A. de Roos, et al. Incremental prognostic value of multi-slice computed tomography coronary angiography over coronary artery calcium scoring in patients with suspected coronary artery disease Eur. Heart J., June 29, 2009; (2009) ehp272v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Chan, J. L. Sun, L. K. Newby, L. K. Shaw, M. Lin, E. D. Peterson, R. M. Califf, D. F. Kong, and M. T. Roe Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction Circulation, June 23, 2009; 119(24): 3110 - 3117. [Abstract] [Full Text] [PDF] |
||||
![]() |
C P Gale, S O M Manda, B A Cattle, C F Weston, J S Birkhead, P D Batin, A S Hall, and R M West The authors' reply: Heart, June 15, 2009; 95(12): 1019 - 1020. [Full Text] [PDF] |
||||
![]() |
APPRAISE Steering Committee and Investigators Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial Circulation, June 9, 2009; 119(22): 2877 - 2885. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Lopes, L. E. Elliott, H. D. White, J. S. Hochman, F. Van de Werf, D. Ardissino, T. T. Nielsen, W. Douglas Weaver, P. Widimsky, P. W. Armstrong, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial Eur. Heart J., June 6, 2009; (2009) ehp213v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Brieger, K A A Fox, G FitzGerald, K A Eagle, A Budaj, A Avezum, C B Granger, B Costa, F A Anderson Jr, P. G Steg, et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events Heart, June 1, 2009; 95(11): 888 - 894. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Windhausen, A. Hirsch, J. Fischer, P. M. van der Zee, G. T. Sanders, J. P. van Straalen, J. H. Cornel, J. G.P. Tijssen, F. W.A. Verheugt, R. J. de Winter, et al. Cystatin C for Enhancement of Risk Stratification in Non-ST Elevation Acute Coronary Syndrome Patients with an Increased Troponin T Clin. Chem., June 1, 2009; 55(6): 1118 - 1125. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Astroulakis and J. M. Hill Does 'SWITCHing' from heparin to bivalirudin monotherapy result in a bleeding benefit? Eur. Heart J. Suppl., June 1, 2009; 11(suppl_C): C13 - C18. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Mehta, C. B. Granger, W. E. Boden, P. G. Steg, J.-P. Bassand, D. P. Faxon, R. Afzal, S. Chrolavicius, S. S. Jolly, P. Widimsky, et al. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes N. Engl. J. Med., May 21, 2009; 360(21): 2165 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Hillis and R. A. Lange Optimal Management of Acute Coronary Syndromes N. Engl. J. Med., May 21, 2009; 360(21): 2237 - 2240. [Full Text] [PDF] |
||||
![]() |
R. P. Giugliano, J. A. White, C. Bode, P. W. Armstrong, G. Montalescot, B. S. Lewis, A. van `t Hof, L. G. Berdan, K. L. Lee, J. T. Strony, et al. Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes N. Engl. J. Med., May 21, 2009; 360(21): 2176 - 2190. [Abstract] [Full Text] [PDF] |
||||
![]() |
R K Riezebos and G J Laarman The authors' reply: Heart, May 1, 2009; 95(9): 761 - 761. [Full Text] [PDF] |
||||
![]() |
K. A A Fox COURAGE to change practice? Revascularisation in patients with stable coronary artery disease Heart, May 1, 2009; 95(9): 689 - 692. [Full Text] [PDF] |
||||
![]() |
R K Riezebos, E Ronner, E ter Bals, T Slagboom, P C Smits, J M ten Berg, F Kiemeneij, G Amoroso, M S Patterson, M J Suttorp, et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes Heart, May 1, 2009; 95(10): 807 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Scirica, D. A. Morrow, A. Budaj, A. J. Dalby, S. Mohanavelu, J. Qin, J. Aroesty, C. M. Hedgepeth, P. H. Stone, and E. Braunwald Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) Trial J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1411 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chua and A. Ignaszewski Clopidogrel in acute coronary syndromes BMJ, April 14, 2009; 338(apr14_1): b1180 - b1180. [Full Text] |
||||
![]() |
J. L. Anderson Stopping the Hemorrhage: A New Baseline Bleeding Score Brings Us a Step Closer for Patients With Non-ST-Elevation Myocardial Infarction Circulation, April 14, 2009; 119(14): 1846 - 1849. [Full Text] [PDF] |
||||
![]() |
S. Subherwal, R. G. Bach, A. Y. Chen, B. F. Gage, S. V. Rao, L. K. Newby, T. Y. Wang, W. B. Gibler, E. M. Ohman, M. T. Roe, et al. Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score Circulation, April 14, 2009; 119(14): 1873 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Schiele, N. Meneveau, M. F. Seronde, V. Descotes-Genon, J. Oettinger, F. Ecarnot, J.-P. Bassand, and on behalf of the 'Reseau de Cardiologie de Franche Changes in management of elderly patients with myocardial infarction Eur. Heart J., April 2, 2009; 30(8): 987 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Z. Potsis, C. Katsouras, and J. A. Goudevenos Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Angiology, April 1, 2009; 60(2): 148 - 158. [Abstract] [PDF] |
||||
![]() |
D. L. BHATT, K. KOTTKE-MARCHANT, J. H. ALEXANDER, W. F. PEACOCK, and M. S. SABATINE Platelet response in practice: Applying new insights and tools for testing and treatment Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_1): S24 - S32. [Full Text] [PDF] |
||||
![]() |
D J Kurz, A Bernstein, K Hunt, D Radovanovic, P Erne, Z Siudak, and O Bertel Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model Heart, April 1, 2009; 95(8): 662 - 668. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hirsch, F. Windhausen, J. G.P. Tijssen, A. J.M. Oude Ophuis, W. J. van der Giessen, P. M. van der Zee, J. H. Cornel, F. W.A. Verheugt, R. J. de Winter, and for the Invasive versus Conservative Treatment in Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias Eur. Heart J., March 2, 2009; 30(6): 645 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tricoci, J. M. Allen, J. M. Kramer, R. M. Califf, and S. C. Smith Jr Scientific Evidence Underlying the ACC/AHA Clinical Practice Guidelines JAMA, February 25, 2009; 301(8): 831 - 841. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Yan, R. T. Yan, T. Huynh, A. Casanova, F. E. Raimondo, D. H. Fitchett, A. Langer, S. G. Goodman, and for the Canadian Acute Coronary Syndrome Registry Understanding Physicians' Risk Stratification of Acute Coronary Syndromes: Insights From the Canadian ACS 2 Registry Arch Intern Med, February 23, 2009; 169(4): 372 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. van Werkhoven, J. D. Schuijf, O. Gaemperli, J. W. Jukema, E. Boersma, W. Wijns, P. Stolzmann, H. Alkadhi, I. Valenta, M. P.M. Stokkel, et al. Prognostic value of multislice computed tomography and gated single-photon emission computed tomography in patients with suspected coronary artery disease. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 623 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Aoki, A. J. Lansky, R. Mehran, J. Moses, M. E. Bertrand, B. T. McLaurin, D. A. Cox, A. M. Lincoff, E. M. Ohman, H. D. White, et al. Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial Circulation, February 10, 2009; 119(5): 687 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Body, S Carley, G McDowell, J Ferguson, and K Mackway-Jones Can a modified thrombolysis in myocardial infarction risk score outperform the original for risk stratifying emergency department patients with chest pain? Emerg. Med. J., February 1, 2009; 26(2): 95 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Swanson, G Montalescot, K A Eagle, S G Goodman, W Huang, D Brieger, G Devlin, and for the GRACE Investigators Delay to angiography and outcomes following presentation with high-risk, non-ST-elevation acute coronary syndromes: results from the Global Registry of Acute Coronary Events Heart, February 1, 2009; 95(3): 211 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.A. Katus, E. Giannitsis, A.S. Jaffe, and K. Thygesen Higher sensitivity troponin assays: Quo vadis? Eur. Heart J., January 2, 2009; 30(2): 127 - 128. [Full Text] [PDF] |
||||
![]() |
A. M. Jansson, H. Rosjo, T. Omland, T. Karlsson, M. Hartford, A. Flyvbjerg, and K. Caidahl Prognostic value of circulating chromogranin A levels in acute coronary syndromes Eur. Heart J., January 1, 2009; 30(1): 25 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Eggers, A. S. Jaffe, L. Lind, P. Venge, and B. Lindahl Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making Clin. Chem., January 1, 2009; 55(1): 85 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lordkipanidze, C. Pharand, T. A. Nguyen, E. Schampaert, D. A. Palisaitis, and J. G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur. Heart J., December 1, 2008; 29(23): 2877 - 2885. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF] |
||||
![]() |
S. R. Mehta, W. E. Boden, J. W. Eikelboom, M. Flather, P. G. Steg, A. Avezum, R. Afzal, L. S. Piegas, D. P. Faxon, P. Widimsky, et al. Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes: An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials Circulation, November 11, 2008; 118(20): 2038 - 2046. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schmidinger, C. C. Zielinski, U. M. Vogl, A. Bojic, M. Bojic, C. Schukro, M. Ruhsam, M. Hejna, and H. Schmidinger Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., November 10, 2008; 26(32): 5204 - 5212. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Jeger, D. Radovanovic, P. R. Hunziker, M. E. Pfisterer, J.-C. Stauffer, P. Erne, P. Urban, and for the AMIS Plus Registry Investigators Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock Ann Intern Med, November 4, 2008; 149(9): 618 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Tziakas, G. K. Chalikias, I. K. Tentes, D. Stakos, S. V. Chatzikyriakou, K. Mitrousi, A. X. Kortsaris, J. C. Kaski, and H. Boudoulas Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome Eur. Heart J., November 2, 2008; 29(22): 2713 - 2722. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Goran Suggestion to list acute aortic dissection as a possible cause of type 2 myocardial infarction (according to the universal definition) Eur. Heart J., November 2, 2008; 29(22): 2819 - 2820. [Full Text] [PDF] |
||||
![]() |
M. Zimarino and R. De Caterina Long-term treatment strategies for atherothrombotic disease: do platelets define the course? Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I8 - I13. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sanz-Ruiz and F. Fernandez-Aviles European perspective on the use of antiplatelet agents in atherothrombotic disease Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I14 - I18. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Betriu Clinical implications of the results of recent atherothrombotic trials on patient management Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I30 - I32. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Hermansen, M. Hansen, M. Roaldsen, S. Muller, O.-J. How, and T. Myrmel Utilization and outcome of coronary revascularization and valve procedures in acute heart failure - an evaluation based on the classification from the European Society of Cardiology Interactive CardioVascular and Thoracic Surgery, October 1, 2008; 7(5): 833 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Eggers, T. Kempf, T. Allhoff, B. Lindahl, L. Wallentin, and K. C. Wollert Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain Eur. Heart J., October 1, 2008; 29(19): 2327 - 2335. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Pundziute, J. D. Schuijf, J. W. Jukema, I. Decramer, G. Sarno, P. K. Vanhoenacker, E. Boersma, J. H.C. Reiber, M. J. Schalij, W. Wijns, et al. Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis Eur. Heart J., October 1, 2008; 29(19): 2373 - 2381. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442. [Full Text] [PDF] |
||||
![]() |
K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail, October 1, 2008; 10(10): 933 - 989. [Full Text] [PDF] |
||||
![]() |
R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1095 - 1103. [Full Text] [PDF] |
||||
![]() |
G. Y H Lip Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention BMJ, September 12, 2008; 337(sep12_1): a840 - a840. [Full Text] |
||||
![]() |
P. G. Steg, A. Kerner, F. Van de Werf, J. Lopez-Sendon, J. M. Gore, G. FitzGerald, L. J. Feldman, F. A. Anderson, A. Avezum, and for the Global Registry of Acute Coronary Events ( Impact of In-Hospital Revascularization on Survival in Patients With Non-ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure Circulation, September 9, 2008; 118(11): 1163 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. White, E. M. Ohman, A. M. Lincoff, M. E. Bertrand, A. Colombo, B. T. McLaurin, D. A. Cox, S. J. Pocock, J. A. Ware, S. V. Manoukian, et al. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial J. Am. Coll. Cardiol., September 2, 2008; 52(10): 807 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ferrari Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection Eur. Heart J. Suppl., September 1, 2008; 10(suppl_G): G13 - G20. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Pepine Provoked Coronary Spasm and Acute Coronary Syndromes J. Am. Coll. Cardiol., August 12, 2008; 52(7): 528 - 530. [Full Text] [PDF] |
||||
![]() |
R. D. Lopes, K. P. Alexander, G. Marcucci, H. D. White, S. Spinler, J. Col, P. E. Aylward, R. M. Califf, and K. W. Mahaffey Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Eur. Heart J., August 1, 2008; 29(15): 1827 - 1833. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Chan, K. W. Mahaffey, L. J. Sun, K. S. Pieper, H. D. White, P. E. Aylward, J. J. Ferguson, R. M. Califf, and M. T. Roe Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 369 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O'Donoghue, W. E. Boden, E. Braunwald, C. P. Cannon, T. C. Clayton, R. J. de Winter, K. A. A. Fox, B. Lagerqvist, P. A. McCullough, S. A. Murphy, et al. Early Invasive vs Conservative Treatment Strategies in Women and Men With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Meta-analysis JAMA, July 2, 2008; 300(1): 71 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Schiele, N. Meneveau, and J.-P. Bassand Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer? Eur. Heart J., June 2, 2008; 29(12): 1475 - 1477. [Full Text] [PDF] |
||||
![]() |
H. D. White, D. P. Chew, J. W. Hoekstra, C. D. Miller, C. V. Pollack Jr, F. Feit, A. M. Lincoff, M. Bertrand, S. Pocock, J. Ware, et al. Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1734 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weber and C. Hamm Novel biomarkers--the long march from bench to bedside Eur. Heart J., May 1, 2008; 29(9): 1079 - 1081. [Full Text] [PDF] |
||||
![]() |
J.-P. Bassand Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm Heart, May 1, 2008; 94(5): 661 - 666. [Full Text] [PDF] |
||||
![]() |
J.-P. Bassand Unmet needs in antiplatelet therapy Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D3 - D11. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Holmvang and H. Mickley Review: Gender differences following percutaneous coronary intervention Therapeutic Advances in Cardiovascular Disease, April 1, 2008; 2(2): 109 - 113. [Abstract] [PDF] |
||||
![]() |
M. Arca, B. Conti, A. Montali, P. Pignatelli, F. Campagna, F. Barilla, G. Tanzilli, R. Verna, A. Vestri, C. Gaudio, et al. C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 752 - 757. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G.G. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C1 - C7. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Bassand The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C22 - C29. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Mehta Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C14 - C21. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Ruiz-Nodar, F. Marin, J. A. Hurtado, J. Valencia, E. Pinar, J. Pineda, J. R. Gimeno, F. Sogorb, M. Valdes, and G. Y.H. Lip Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation: Implications for Bleeding Risk and Prognosis J. Am. Coll. Cardiol., February 26, 2008; 51(8): 818 - 825. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Roffi and D. Mukherjee Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? Eur. Heart J., February 2, 2008; 29(4): 429 - 431. [Full Text] [PDF] |
||||
![]() |
J.-P. Bassand and C. W. Hamm Non-ST-segment elevation acute coronary syndromes: an algorithm for decision: reply Eur. Heart J., January 2, 2008; 29(2): 280 - 281. [Full Text] [PDF] |
||||
![]() |
O. M. Jolobe Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes Eur. Heart J., January 2, 2008; 29(2): 277 - 277. [Full Text] [PDF] |
||||
![]() |
M. E. Bertrand, J. P. Collet, and G. Montalescot Non-ST-segment elevation acute coronary syndromes: an algorithm for decision Eur. Heart J., January 2, 2008; 29(2): 279 - 280. [Full Text] [PDF] |
||||
![]() |
C. Rapezzi, E. Biagini, and A. Branzi Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., January 2, 2008; 29(2): 277 - 278. [Full Text] [PDF] |
||||
![]() |
A. K. Gitt and A. Betriu Antiplatelet therapy in acute coronary syndromes Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12. [Abstract] [Full Text] [PDF] |
||||



















